There hasn't been a significant rise in Astrazeneca, despite the approval of the vaccine in the UK, the orders from Indonesia and Taiwan and reassuring news about the effectiveness of the vaccine. I think some negative publicity about the vaccine effectiveness in comparison to the other vaccines in the US could have led to this consolidation, but even if the other...
